Was wondering what kind of information Dr. Patters
Post# of 153839
(Total Views: 756)
Posted On: 05/31/2020 8:46:06 AM
Was wondering what kind of information Dr. Patterson has in regards to the patients already enrolled in the M-M trial:
Under Other Outcome Measures: We can see the following:
So, basically he is measuring the same parameters he referred to in his paper: IL-B, IL-6, IL-8, CCL-5 (with occupancy tests as well), CD8, CD3, CD4, T cells, Monocytes, Plasma Viral Loads
This is why he said that he was seeing some exciting results and that the trial had been well tailored to the results he had obtained before.
And this is why he KNOWS, if one has experience with making this measurements after Leronlimab was injected (from the Montefiori group) and, then, receives 50 samples of blood (blinded)… wouldn't he able to tell the difference between the Placebo and the drug ones ??
Hell Yes !!!
Not only that, he must be documenting all the measurement with exquisite detail … plots, statistics, time-lines and so on.
By now a picture must be in his brain ... I surely hope this is a collection of sample clouds separated by large distances with very low p-numbers between them (as in the original paper).
These will result in clinical outcomes and these will result in approval if it is what I think it is
Let's hope for large enrollment numbers this coming week !!!
Under Other Outcome Measures: We can see the following:
Quote:
Change in size of lesion area by chest radiograph or CT [ Time Frame: Day 14 ]
Change from baseline in serum cytokine and chemokine levels [ Time Frame: Days 3, 7, and 14 ]
Change from baseline in CCR5 receptor occupancy levels for Tregs and macrophages [ Time Frame: Days 3, 7, and 14 ]
Change from baseline in CD3+, CD4+ and CD8+ T cell count [ Time Frame: Days 3, 7, and 14 ]
So, basically he is measuring the same parameters he referred to in his paper: IL-B, IL-6, IL-8, CCL-5 (with occupancy tests as well), CD8, CD3, CD4, T cells, Monocytes, Plasma Viral Loads
This is why he said that he was seeing some exciting results and that the trial had been well tailored to the results he had obtained before.
And this is why he KNOWS, if one has experience with making this measurements after Leronlimab was injected (from the Montefiori group) and, then, receives 50 samples of blood (blinded)… wouldn't he able to tell the difference between the Placebo and the drug ones ??
Hell Yes !!!
Not only that, he must be documenting all the measurement with exquisite detail … plots, statistics, time-lines and so on.
By now a picture must be in his brain ... I surely hope this is a collection of sample clouds separated by large distances with very low p-numbers between them (as in the original paper).
These will result in clinical outcomes and these will result in approval if it is what I think it is
Let's hope for large enrollment numbers this coming week !!!
(12)
(0)